| Document |
Document Title |
|
WO/2024/102219A1 |
A method of treating acne, of treating UV or radiation induced injury, of reducing the appearance of scars, and/or of treating mucositis, including topically applying a composition including CAPE to a human or other mammal in need thereo...
|
|
WO/2024/100421A1 |
The invention relates to therapeutic uses of SARM1 agents (e.g. molecule that causes neurodegeneration and/or neuronal dysfunction in a SARM1 -dependent manner) such as Vacor, metabolites, analogs, and derivatives thereof for treating an...
|
|
WO/2024/099404A1 |
The present application relates to a nitrogen-containing spirocyclic compound, a pharmaceutical composition and a use thereof. The nitrogen-containing spirocyclic compound has the structural formula represented by formula (I). The compou...
|
|
WO/2024/098093A1 |
A composition for the treatment of acne and rosacea that comprises Caprylic/Capric Triglyceride, Glycerin, Melaleuca Alternifolia (Tea Tree) Leaf Oil, Cetearyl Alcohol, Prunus Amygdalus (Sweet Almond) Dulcis Oil, Olea Europaea (Olive) Fr...
|
|
WO/2024/098136A1 |
A polyethylene glycol (PEG) prepolymer is disclosed herein. The PEG prepolymer comprises a reaction product of an amine-reactive PEG and a protease degradable peptide. The reaction product comprises the formula [Acryl-PEG-peptide-PEG-Acr...
|
|
WO/2024/100219A1 |
The present invention relates to an active ingredient consisting of the following molecules: acetic acid, butyric acid, lactic acid and propionic acid, and/or a salt and/or an ester and/or an anhydride of one or more of these molecules, ...
|
|
WO/2024/101489A1 |
The present invention relates to a method for preparing an external gel formulation for the treatment of itching containing a propionic acid-based non-steroidal anti-inflammatory drug as an active ingredient, characterized by adding and ...
|
|
WO/2024/098210A1 |
The present invention relates to the technical field of drug research and development, and specifically relates to an aryl carboxylic acid compound, in particular to a use of the aryl carboxylic acid compound in the preparation of an Mrg...
|
|
WO/2024/100216A1 |
The present invention concerns a composition comprising: an inactivated strain of lactobacillus; and an aqueous extract obtained from grape seeds and/or skins, and its use e.g. in cosmetics as an anti-ageing agent.
|
|
WO/2024/098848A1 |
The present application relates to a preparation method for a bird's nest peptide: mixing bird's nest and water, and stewing to prepare a cooked bird's nest material; homogenizing the cooked bird's nest material to prepare a bird's nest ...
|
|
WO/2024/100755A1 |
[Problem] The present invention addresses the problem of providing a composition for improving the intestinal barrier function and/or strengthening intestinal epithelial tight junctions that contains Lactobacillus plantarum L-137 or a pr...
|
|
WO/2024/102456A1 |
The present disclosure relates to articles that are therapeutic coverings and wraps comprising a substrate and a releasable therapeutic agent in contact with or attached to one another. The articles comprising therapeutic coverings and w...
|
|
WO/2024/086100A9 |
Methods and formulations for the systemic protection of an animal from exposure to a photocarcinogen. The methods include orally administering to an animal a formulation comprising a therapeutically effective amount of one or more UV-abs...
|
|
WO/2024/100293A1 |
The present invention relates to the field of cosmetics and in particular to an aqueous topical hair care formulation for topical administration.
|
|
WO/2024/100919A1 |
Provided is a novel agent which can induce an effect of inhibiting the expression of a pruritus-related gene and is mainly applicable to human skin or the like. The agent for use in the prevention of pruritus according to the present d...
|
|
WO/2024/101703A1 |
The present specification relates to a composition for external application on the skin for radiation protection, and a method for preparing same. According to the present disclosure, the composition can directly protect the skin by comp...
|
|
WO/2023/219376A3 |
The present invention relates to: a natural composition for inhibiting the production of carcinogenic N-nitrosamine in the stomach and intestines and promoting the production of nitric oxide in the intestines; and a use thereof. The natu...
|
|
WO/2024/099403A1 |
A thioether compound having a soft drug property and a use thereof, and a pharmaceutical composition and a use thereof. The compound has a structural formula of formula I. A thioether structure in the compound has pharmacological activit...
|
|
WO/2024/101440A1 |
Provided is a compound represented by formula (1): [in the formula, the definitions for variables are as defined in the description] or a pharmaceutically acceptable salt thereof.
|
|
WO/2024/098361A1 |
The present application relates to the technical field of bio-pharmaceuticals. The present application particularly relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3'-untranslate...
|
|
WO/2024/064640A3 |
Disclosed herein are chimeric antigen receptors (CARs) comprising an antigen binding site that recognizes citrullinated polypeptides. Citru llinated polypeptides, such as citrullinated vimentin, are expressed in the skin lesions of subje...
|
|
WO/2024/092361A1 |
There is provided the use of a functional thylakoid extract, particularly in admixture with a physiologically acceptable carrier, in pharmaceutical application for wound healing. The thylakoid extract may be used to treat skin or mucosal...
|
|
WO/2024/096825A1 |
The invention is a wound healing composition containing Lucilia sericata larval secretion and cyanobacteria. It contains 63.3-66.66% by weight of Lucilia sericata larval secretion, 31.7-33.33% by weight of cyanobacteria and 5-0.01% by we...
|
|
WO/2024/096418A1 |
The present invention relates to a pharmaceutical or cosmetics composition having anti-inflammatory, anti-pruritic, anti-allergenic, and deodorant effect, the composition comprising composite extract of Lagerstroemia indica and Persicari...
|
|
WO/2024/095232A1 |
A method of performing photodynamic therapy is provided. The method includes applying, to the skin of a patient, a topical composition. The topical composition includes 5- aminolevulinic acid (ALA) hydrochloride, and a vehicle comprising...
|
|
WO/2024/097714A1 |
Methods for treating moderate-to-severe atopic dermatitis of the hand and/or foot in a subject are provided. In one aspect, the methods comprise administering to the subject one or more doses of an interleukin-4 receptor (IL-4R) antagoni...
|
|
WO/2024/097316A1 |
The present invention relates to methods for treating patients with systemic sclerosis, comprising administering to a patient in need thereof a therapeutically effective amount of a soluble guanylate cyclase (sGC) activator of formula (I...
|
|
WO/2024/094841A1 |
Provided herein are methods for Alagille syndrome (ALGS) with an ileal bile acid transport (IBAT) inhibitor such as odevixibat, or a pharmaceutically acceptable salt thereof. Such methods can include reducing pruritus score, serum bile a...
|
|
WO/2024/094224A2 |
Provided in the present invention are a PBase protein, a fusion protein, a nucleic acid, a gene integration system, a gene delivery system and the use. The PBase protein retains the abilities of binding to the ITR sequences of a Piggybac...
|
|
WO/2024/096497A1 |
The present invention provides a pharmaceutical composition containing N-nonyldeoxynojirimycin for the suppression, alleviation, or treatment of skin itching; and a cosmetic composition for the suppression, alleviation, or palliation of ...
|
|
WO/2024/093625A1 |
The present invention relates to the technical field of biomedicine. Disclosed is a linolenic acid-derived ceramide, which has a structure of general formula I or an isomer of general formula I: (I), wherein R1 is selected from (II) or (...
|
|
WO/2024/095793A1 |
[Problem] To provide an antioxidant cosmetic. [Solution] Provided is an antioxidant cosmetic containing at least one component selected from the group consisting of (A) a cyclic carboxamide derivative having a specific structure or a sal...
|
|
WO/2024/096692A1 |
The present invention relates to a composition for improving skin condition, containing a Sambucus nigra callus culture or an extract thereof as an active ingredient. The Sambucus nigra callus culture or extract thereof according to the ...
|
|
WO/2024/097606A1 |
The present disclosure relates to certain AHR agonist compounds, for example, having a general formula (I) to pharmaceutical compositions comprising the compounds, and to methods of using the compounds to treat immune-mediated diseases, ...
|
|
WO/2024/093673A1 |
The present application discloses a method for separating a human hair follicle-derived papilla cell. The present application provides a method for separating a hair follicle-derived papilla cell in vitro. The method comprises the follow...
|
|
WO/2024/096401A1 |
One aspect relates to a pharmaceutical composition for wound healing or skin tissue regeneration, the pharmaceutical composition containing an extracellular matrix and a kelp extract. According to one aspect, the extracellular matrix and...
|
|
WO/2024/097290A1 |
This document relates to methods and materials for assessing and/or treating mammals (e.g., humans) having an inflammatory skin disease (e.g., erythroderma such as refractory erythroderma). For example, methods and materials that can be ...
|
|
WO/2024/096569A1 |
The present invention relates to a composition, more preferably, a transdermally- or topically-administered composition, comprising, as an active ingredient, a thienopyridine compound of chemical formula 1 or a pharmaceutically acceptabl...
|
|
WO/2024/097836A1 |
Provided herein are assays and methods for identifying which of a plurality of drugs is responsible for causing a delayed-type drug hypersensitivity reaction (dtDHR) in a patient.
|
|
WO/2024/091701A1 |
Provided herein are compositions and methods for tissue repair. In particular, the compositions and methods described herein find use in repairing, regenerating, and modulating fibrosis and inflammation in a variety of tissues such as, f...
|
|
WO/2024/087985A1 |
In order to solve the problems of insufficient heat resistance and insufficient structural strength of an existing natural bactericide microneedle, provided is a microneedle patch for preventing or treating skin infections. The microneed...
|
|
WO/2024/090634A1 |
The present disclosure relates to a composition comprising a K-opioid receptor agonist for preventing, ameliorating, or treating diseases related to skin whitening or pigmentation.
|
|
WO/2024/088395A1 |
Disclosed in the present invention are a series of bridged-ring compounds and a pharmaceutical use thereof, and in particular, disclosed are a compound as shown in formula (I) and a pharmaceutically acceptable salt thereof.
|
|
WO/2024/088282A1 |
The present invention provides a pyridazine compound as shown in formula (II), a preparation method therefor, and uses thereof. Also disclosed are uses of the compound of the present invention or the pharmaceutical composition thereof in...
|
|
WO/2024/088175A1 |
Disclosed in the present disclosure are a gRNA targeting VEGFA, a gene editing system, and the use thereof. The gRNA in the present disclosure comprises a guide sequence which has at least 80% sequence identity to any one of SEQ ID NOs: ...
|
|
WO/2024/089076A1 |
The invention relates to a glutamine/tannic acid complex and to a pharmaceutical or cosmetic composition comprising said complex. The present invention also relates to said complex as well as to said composition for use in the prevention...
|
|
WO/2024/091889A1 |
Flt3L is a soluble, focused signal that can expand the dendritic cell compartment. The disclosure provides for methods for regenerating tissue, for preventing wound formation, or for treating wounds in a subject. The methods are achieved...
|
|
WO/2024/091513A1 |
The present disclosure provides polymeric matrices comprising calreticulin (CRbT) and methods of producing and using such matrices. The polymeric matrices are useful in treatment of wounds (e.g., chronic diabetic wound).
|
|
WO/2024/091572A1 |
The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided...
|
|
WO/2024/088110A1 |
Provided are a heterocyclic macrocyclic compound containing an indazole structure and used as a protein kinase inhibitor, and a preparation method therefor. The compound has the structure represented by general formula (I). Additionally ...
|
